Becker's Healthcare March 22, 2024
Paige Twenter

On March 22, the FDA granted emergency use authorization to Pemgarda, a COVID-19 preventive medication, for patients 12 and older.

Pemgarda (pemivibart) is a monoclonal antibody that targets the SARS-CoV-2 spike protein. Clinicians are authorized to administer the drug, which must be infused for at least an hour and be followed by a repeat dose every three months.

...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
FDA Approves First Biosimilar of Xolair
Opinion: STAT+: How will the Center for Biologics Evaluation and Research change under RFK Jr.?
How the FDA Opens the Door to Risky Chemicals in America’s Food Supply
FDA OKs First Gene Therapy Implant for a Rare Eye Disease
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder

Share This Article